<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In 1994 <z:hpo ids='HP_0001061'>acne</z:hpo> should be a very treatable disorder </plain></SENT>
<SENT sid="1" pm="."><plain>However there are a significant number of patients who do not respond as well to therapy as they ought </plain></SENT>
<SENT sid="2" pm="."><plain>Compliance is an important reason for poor response </plain></SENT>
<SENT sid="3" pm="."><plain>Inappropriate therapy is another common reason </plain></SENT>
<SENT sid="4" pm="."><plain>An increasing problem are patients with resistance of P. <z:hpo ids='HP_0001061'>acnes</z:hpo> to commonly used antibiotics; 39% of our patients have such resistance </plain></SENT>
<SENT sid="5" pm="."><plain>Within this sub-group the commonest antibiotics causing problems are <z:chebi fb="2" ids="42355,48923">Erythromycin</z:chebi> and <z:chebi fb="0" ids="3745">Clindamycin</z:chebi> (69%) </plain></SENT>
<SENT sid="6" pm="."><plain>Resistance is seen in 20% of such subjects to <z:chebi fb="9" ids="27902">Tetracycline</z:chebi> and <z:chebi fb="0" ids="50845">Vibramycin</z:chebi> and resistance to <z:chebi fb="0" ids="45924">Trimethoprim</z:chebi> is 12% </plain></SENT>
<SENT sid="7" pm="."><plain>Multiple resistance is 14% </plain></SENT>
<SENT sid="8" pm="."><plain>This is an increasing problem and unless attention is given to this problem by the year 2,000 we may have very few safe and successful antibiotics </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="1" ids="50694">Minocycline</z:chebi> is rarely associated with resistance </plain></SENT>
<SENT sid="10" pm="."><plain>Some patients have no resistance and may have a high sebum excretion; this will dilute what otherwise could be effective therapy </plain></SENT>
<SENT sid="11" pm="."><plain>Such patients ought to be given high dose antibiotics such as <z:chebi fb="1" ids="50694">Minocycline</z:chebi> 200 mgs per day, plus appropriate topical therapy </plain></SENT>
<SENT sid="12" pm="."><plain>Dianette plus 50- 100 mg <z:chebi fb="0" ids="50742">cyproterone</z:chebi> remains an alternative therapy in females </plain></SENT>
<SENT sid="13" pm="."><plain>Some patients will fail to respond with these regimes and require <z:chebi fb="0" ids="6067">Isotretinoin</z:chebi> </plain></SENT>
<SENT sid="14" pm="."><plain>Patients who require oral <z:chebi fb="0" ids="6067">Isotretinoin</z:chebi> are those with non-responding moderate <z:hpo ids='HP_0001061'>acne</z:hpo>, patients who scar, plus patients with unusual but specific problems </plain></SENT>
<SENT sid="15" pm="."><plain>These include <z:hpo ids='HP_0001061'>Acne</z:hpo> Fulminans, <z:e sem="disease" ids="C0035854" disease_type="Disease or Syndrome" abbrv="">Rosacea</z:e> Fulminans, <z:hpo ids='HP_0001061'>Acne</z:hpo> Conglobata, <z:mp ids='MP_0001795'>Gram-negative</z:mp> <z:mp ids='MP_0000376'>folliculitis</z:mp>, Gross <z:e sem="disease" ids="C0036508" disease_type="Disease or Syndrome" abbrv="">Seborrhoea</z:e>, <z:e sem="disease" ids="C0005887" disease_type="Mental or Behavioral Dysfunction" abbrv="">Dysmorphophobia</z:e>, Mature <z:hpo ids='HP_0001061'>Acne</z:hpo> and <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Aperts Syndrome</z:e> </plain></SENT>
<SENT sid="16" pm="."><plain>The choice of dose varies, often according to personal experience and cost </plain></SENT>
<SENT sid="17" pm="."><plain>Most physicians prescribe 0.5-1.0 mg/day for 4 months </plain></SENT>
<SENT sid="18" pm="."><plain>Fifteen percent require 5-12 months therapy </plain></SENT>
<SENT sid="19" pm="."><plain>Frequent reasons for prolonged therapy are macrocomedones and <z:hpo ids='HP_0000147'>polycystic ovary</z:hpo> syndrome </plain></SENT>
<SENT sid="20" pm="."><plain>Relapse post therapy occurs in 30%; relapse after 3 years is unusual </plain></SENT>
<SENT sid="21" pm="."><plain>Repeat doses can be given </plain></SENT>
<SENT sid="22" pm="."><plain>The results are predictive and successful </plain></SENT>
<SENT sid="23" pm="."><plain>The treatment of certain troublesome side effects also will be discussed as will the use of <z:chebi fb="0" ids="6067">Isotretinoin</z:chebi> in <z:e sem="disease" ids="C0442893" disease_type="Disease or Syndrome" abbrv="">systemic disease</z:e> </plain></SENT>
<SENT sid="24" pm="."><plain><z:chebi fb="0" ids="6067">Isotretinoin</z:chebi> orally is so effective that it ought to be given sooner rather than later to minimise <z:hpo ids='HP_0100699'>scarring</z:hpo> about which still only a little can be done to help the patient </plain></SENT>
</text></document>